AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Brokerages

AstraZeneca PLC (LON:AZN) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is £153.33.

AZN has been the subject of several research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a £180 target price on shares of AstraZeneca in a research report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a report on Thursday, June 11th. Finally, Citigroup lifted their price objective on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a report on Friday, April 10th.

AstraZeneca Trading Down 0.3%

Shares of AstraZeneca stock opened at £140.24 on Friday. AstraZeneca has a 1 year low of £101.03 and a 1 year high of £157.32. The firm has a market cap of £217.49 billion, a PE ratio of 21.12, a P/E/G ratio of 0.86 and a beta of 0.21. The stock has a fifty day moving average price of £138.04 and a 200-day moving average price of £141.13. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.